Navigation Links
Barrier Therapeutics Announces Liarozole Phase 2/3 Study Results in,Lamellar Ichthyosis

dermatitis complicated by documented candidiasis; and Solage(R) (mequinol 2.0%, tretinoin 0.01%) Topical Solution, for solar lentigines. Barrier Therapeutics has other product candidates in various stages of clinical development for the treatment of a range of dermatological conditions, including onychomycosis, psoriasis, acne, skin allergies, and acute fungal infections. The company is headquartered in Princeton, New Jersey and has wholly owned subsidiaries in Geel, Belgium and Ontario, Canada. More information about Barrier Therapeutics can be found on its corporate website at: www.barriertherapeutics.com.

Xolegel, Vusion and Solage are trademarks of Barrier Therapeutics, Inc.

Safe Harbor Statement

In addition to historical facts or statements of current condition, this press release contains forward-looking statements within the meaning of the "Safe Harbor" provisions of The Private Securities Litigation Reform Act of 1995, including statements regarding the Company's business development and clinical development plans for liarozole, and the potential therapeutic benefits of RAMBAs in general and liarozole in particular. Forward-looking statements provide Barrier's current expectations or forecasts of future events. Barrier's performance and financial results could differ materially from those reflected in these forward-looking statements due to the marketplace acceptance of Barrier's products, Barrier's ability to execute its commercial and clinical strategy, the decisions of regulatory authorities, the results of clinical trials and strategic decisions regarding its pipeline, general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industries generally. For a discussion of these and other risks and uncertainties that may effect the forward-looking statements, please see the risk factors in the company's Quarterly Report on Form 10-Q for the period ended March 31, 2007 which is on file
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
5. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
6. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
7. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
8. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
9. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
10. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
11. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
Post Your Comments:
(Date:8/21/2014)... SAN FRANCISCO , Aug. 21, 2014 ... U.S. Food and Drug Administration (FDA) has ... to detect atrial fibrillation (AFib), the most ... analysis process (algorithm) instantly detects if patients ... recordings taken on the mobile phone based ...
(Date:8/21/2014)...  The board of directors of VirtualScopics, Inc. (NASDAQ: ... trial imaging solutions, today announced that James Groff ... immediately.  Mr. Groff has held the role of acting ... in January 2006 as an accounting manager and was ... the board of VirtualScopics asked Jim to assume the ...
(Date:8/21/2014)... , Aug. 21, 2014 /CNW/ - Bedrocan Cannabis ... three independent members to its Board of Directors, ... experience of the company, a leading licensed producer ... . Internationally, Bedrocan has 13 years, experience in ... in seven countries, including Canada. ...
Breaking Medicine Technology:AliveCor Receives First FDA Clearance to Detect a Serious Heart Condition in an ECG on a Mobile Device 2VirtualScopics, Inc. Names James Groff Chief Financial Officer 2VirtualScopics, Inc. Names James Groff Chief Financial Officer 3VirtualScopics, Inc. Names James Groff Chief Financial Officer 4Senior Life Sciences Executives Join Bedrocan as Independent Directors 2Senior Life Sciences Executives Join Bedrocan as Independent Directors 3
... BEIJING, Oct. 24 /PRNewswire-Asia-FirstCall/ -- Sinovac Biotech Ltd. (Nasdaq: ... products in China, announced today that it has been ... Prevention (Beijing CDC) as one of the five manufacturers ... Beijing. As part of the bidding process, ...
... 24 The National Community Pharmacists ... Jaeger as Executive Vice President and CEO, heralding ... the association,s recent accomplishments and lead it to ... of, independent community pharmacies and the patients they ...
Cached Medicine Technology:Sinovac Selected by Beijing CDC to Supply Seasonal Flu Vaccine Anflu(R) to Beijing Citizens 2Sinovac Selected by Beijing CDC to Supply Seasonal Flu Vaccine Anflu(R) to Beijing Citizens 3NCPA Announces Kathleen Jaeger as CEO 2
(Date:8/21/2014)... August 21, 2014 The new ... from Lockton Companies and builds on Accountable Health ... cellular glucometer, combined with Accountable Health’s robust member ... analytic capabilities and adds a custom incentive platform ... eye exams, provider visits, HbA1c testing and more. ...
(Date:8/21/2014)... 21, 2014 Relias Learning, the leader ... and human services markets, announced the latest release of ... the Tin Can API. , “Supporting the Tin ... the most advanced mobile learning capabilities and the ability ... tools and techniques,” says Jim Triandiflou, CEO of Relias ...
(Date:8/21/2014)... to be elicited by T-type calcium channels in ... regulate influxes of calcium. These channels enable thalamic ... the neurons to enter a hyper-excited state. , ... firing and absence seizures, the researchers conducted an ... gene targeting techniques to delete the T-type calcium ...
(Date:8/21/2014)... August 21, 2014 ... Peripheral Vascular Devices Market by Angioplasty ... Catheter (IVUS, OCT), IVC Filter (Retrievable), ... 2018" analyzes and studies the major ... the U.S. and Canada. , Browse ...
(Date:8/21/2014)... mynt welcomes industry leaders Rob and ... its growing company. Since its pre-launch in April, mynt ... and continues to gain momentum leading up to its ... Tiffanie came into network marketing by chance. Tiffanie worked ... network marketing companies. Tiffanie needed help at one particular ...
Breaking Medicine News(10 mins):Health News:Accountable Health Expands Diabetes Management Solutions to Address Gaps in Provider Care 2Health News:Accountable Health Expands Diabetes Management Solutions to Address Gaps in Provider Care 3Health News:Relias Learning Announces Support for Tin Can API 2Health News:North American Interventional Cardiology and Peripheral Vascular Devices Market worth $5.9 Billion by 2018 - Research Report by MarketsandMarkets 2Health News:North American Interventional Cardiology and Peripheral Vascular Devices Market worth $5.9 Billion by 2018 - Research Report by MarketsandMarkets 3Health News:North American Interventional Cardiology and Peripheral Vascular Devices Market worth $5.9 Billion by 2018 - Research Report by MarketsandMarkets 4Health News:North American Interventional Cardiology and Peripheral Vascular Devices Market worth $5.9 Billion by 2018 - Research Report by MarketsandMarkets 5Health News:Industry Leaders Rob and Tiffanie Moffitt Join mynt 2
... for cancer when they were children have a higher-than-average ... severe in the years following treatment, according to ... of the International Society of Paediatric Oncology (SIOP) in ... Cancer Center and their colleagues say their findings suggest ...
... scientists will receive grants totaling $9.35 million to help ... and traumatic brain injury. The grants from the ... 21, to Dr. Henry Klassen, Leslie M. Thompson, Brian ... Sue and Bill Gross Stem Cell Research Center at ...
... cholesterol-lowering drug reduced the enlarged prostates of hamsters to the ... prostatic hyperplasia (BPH), report researchers at Children,s Hospital Boston and ... Urology. Together, the drugs worked even better. "We don,t ... lowering cholesterol has the potential to reduce BPH in men," ...
... WHAT: Researchers funded by the National Institutes of Health have ... is evolving into two separate species with different traits, ... and potentially require new disease prevention methods. Their findings ... issue of the journal Science . A. ...
... of California, San Diego School of Medicine indicates that parent-only ... that include parents and child, while at the same time ... The results were published today in the advanced online edition ... PhD, associate professor of pediatrics and psychiatry at UC San ...
... -- If you,re a nonsmoker who lives in an apartment, ... smoke, says a new study. Researchers at Roswell Park ... 30 apartments within 11 buildings and found that secondhand smoke ... apartments of nonsmokers. The extent of the secondhand smoke ...
Cached Medicine News:Health News:Childhood cancer survivors face long-term risk of GI complications, study finds 2Health News:UCI stem cell researchers to receive $9.35 million in state funding 2Health News:UCI stem cell researchers to receive $9.35 million in state funding 3Health News:Cholesterol-lowering drug shrinks enlarged prostates in hamster model 2Health News:Parent-only treatment may be equally effective for children who are obese 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: